[Value of triiodothyroacetic acid as suppressive treatment of the thyrotropin secretion in thyroid pathology].
Fifty-six patients were treated with triiodothyroacetic acid (TRIAC) for its suppressive effect on the pituitary-thyroid function. Thirty of these patients had undergone partial thyroidectomy for benign goitre, and among these 14 had developed hyperplasia of the remaining thyroid tissue (group I); 18 presented with homogeneous or nodular goitre (group II); 8 had been thyroidectomized for carcinoma (group III). Before TRIAC was prescribed, thyroid hormones had been used in 33 patients, exerting a suppressive effect on the thyrotropic hormone in 4 patients of group III and producing signs of intolerance in 24 cases. TRIAC was administered in doses of 700-1,750 micrograms/day to all patients of group I and II, and combined with LT4 100 micrograms/day to group III patients. Suppression of the thyrotropic secretion was obtained in all group III patients and in 88 p. 100 of groups I and II patients. Thyroid gland hypertrophy regressed or disappeared in 21 patients of groups I and II, and no relapse or metastasis was observed in group III. TRIAC was well tolerated in all but one patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013959:Thyroid Diseases / Q000188:drug therapy* / Q000378:metabolism; D013963:Thyroid Hormones / Q000627:therapeutic use; D013965:Thyroidectomy; D013972:Thyrotropin / Q000378:metabolism*; D014284:Triiodothyronine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013963:Thyroid Hormones; D014284:Triiodothyronine; C010642:3,3',5-triiodothyroacetic acid; D013972:Thyrotropin
Intérêt de l'acide triiodothyroacétique comme traitement freinateur de la sécrétion thyréotrope en pathologie thyroïdienne.